Industry news

Pfizer runs away with pharma brand ad-spending crown, Nielsen data shows

Beth Snyder Bulik / FiercePharmaMarketing

Pharma companies’ ad spending jumped again last year to $5.6 billion, up from $5.2 billion in 2015, according to Nielsen data. And Pfizer is in large part to thank.

Russian Ministry ready to support pharmaceutical equipment manufacturers

GMP News

Vasily Osmakov, Deputy Minister of Industry and Trade of the Russian Federation, held a meeting to discuss the support measures for manufacturers of equipment that can be used in the pharmaceutical industry. To achieve these goals, Russian companies can benefit from a wide range of existing state support measures described by Vasily Osmakov during the meeting.

14 March 2017

Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended  December 31, 2016 , and provided an update on its development programs.

Global respiratory complications market will surpass $30 billion mark by 2022, says GBI Research

GBI Research

The respiratory complications market is set to grow from $21.8 billion in 2015 to $30.2 billion by 2022, representing a compound annual growth rate of 4.7%, according to business intelligence provider GBI Research.

22% of Russian pharmaceutical manufacturers received GMP certificate

GMP News

According to the analytical department of FBI SID&GP, by the end of 2016, 527 manufacturing licenses were effective in the Russian Federation, which corresponds to 566 production sites in 71 regions. At the same time, 378 sites (69%) have a license for manufacturing and packaging of finished dosage forms and substances, while 185 sites (31%) produce only alcohol-containing solutions, medical gases, etc.

13 March 2017

Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2016.

The new CEOs in biopharma are joining the big players at the billion-dollar chip table

John Carroll / Endpoints News

Every time a new CEO takes over at a biopharma company of some size, the instinctive response is to look for some deal or deals that will help set the tone for the new leader, preferably one that is predictive of a bold — but not reckless — design on future growth.

High U.S. drug prices cover pharma's global R&D—and a whole lot more, study finds

Eric Sagonowsky / FiercePharma

Sure to add fuel to the fiery U.S. drug pricing debate, new work from several health policy experts showed that pharma makes more from platinum pricing in the U.S. than it spends on research around the world.

Pfizer looks at building major gene therapy manufacturing facility in North Carolina

Eric Palmer / Fierce Pharma

Pfizer, which scooped up Bamboo Therapeutics last year in its aim to be a major player in gene therapies, is now looking at building a gene therapy production facility in North Carolina where the biotech is based.

Artificial intelligence for medicine and neurocomputers—international effort

Marchmont Innovation News

An international research team has come up with a self-learning artificial intelligence, a breakthrough that may have wide applications, including therapies to treat human memory dysfunctions. The key participant in the project is the Tomsk State University (TSU). Other developers also include researchers from Germany, Bulgaria, Ukraine, Belarus, and Kazakhstan.